259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

259.8

-1.03%↓

SAN

80.72

+2.25%↑

MRK1

109.9

-0.9%↓

SHL.DE

47.3

-0.55%↓

ARGX

651.8

+0.37%↑

Kodu・Aktsiate loetelu・Pharming Group NV

P
Pharming Group NV

Suletud

1.212 -1.7

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.177

Max

1.24

Põhinäitajad
By Trading Economics
Sissetulek	19M 4.7M
Müük	14M 93M
Aktsiakasum	0.006
Kasumimarginaal	5.035
Töötajad	404

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+91.42% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	6. nov 2025

Turustatistika
By TradingEconomics
Turukapital	229M 847M
Eelmine avamishind	2.91
Eelmine sulgemishind	1.212

Pharming Group NV Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2025, 23:59 UTC

Omandamised, ülevõtmised, äriostud

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8. sept 2025, 22:02 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4 Billion AI Deal With Nebius

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Tron Shares Rise After New Investment From Bravemorning

8. sept 2025, 16:14 UTC

Suurimad hinnamuutused turgudel

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8. sept 2025, 16:13 UTC

Suurimad hinnamuutused turgudel

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8. sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

8. sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8. sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

8. sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8. sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8. sept 2025, 21:47 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4B AI Deal With Nebius

8. sept 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8. sept 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8. sept 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8. sept 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8. sept 2025, 20:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8. sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

8. sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8. sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8. sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

8. sept 2025, 16:59 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8. sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8. sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

8. sept 2025, 16:16 UTC

Tulu

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

8. sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Pharming Group NV Prognoos

Hinnasiht

By TipRanks

91.42% tõus

12 kuu keskmine prognoos

Keskmine 2.45 EUR 91.42%

Kõrge 2.45 EUR

Madal 2.45 EUR

Põhineb 1 Wall Streeti analüütiku instrumendi Pharming Group NV 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

Osta

Hoia

Müü

Põhineb 1 analüütiku instrumendi Pharming Group NV aktsia reitingul - viimase 3 kuu andmed.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.